The BPDCN cell of origin is the plasmacytoid dendritic cell (pDC) precursor. The diagnosis of BPDCN is based on the immunophenotypic diagnostic triad of CD123, CD4, and CD56, as well as other markers.

Researchers have uncovered critical mechanisms linked to metabolic insufficiencies that underlie plasmacytoid dendritic cell ...

Marlise R. Luskin, MD, MSCE, discussed treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and challenging disease.

An expert discusses how blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy derived from ...

The Business Research Company The Business Research Company's Elzonris Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2 ...

Zúñiga believes that interventions that target LDHB or related metabolic pathways could be explored as a way to counteract ...

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive malignancy with fewer than 100 paediatric cases reported. This report details a boy who presented in young childhood with ...

PDC*line is more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including the T-cells specific for neoantigens, and is ...

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast ...